Skip to main content
. 2021 Feb 5;13(4):642. doi: 10.3390/cancers13040642

Figure 6.

Figure 6

Proposed model for targeting the AF9-DOT1L interaction. Disrupting the AF9-DOT1L PPI downregulates H3K79me and HoxA9 and Meis1 expression leading to cell differentiation and cell death. In contrast, in non-leukemic bone marrow (BM), the AF9-DOT1L interaction is dispensable wherein hematopoietic stem and progenitor cells are sustained.